EXPEDIA GROUP INC (EXPE)       120.2  +1.13 (+0.95%)

120.2  +1.13 (+0.95%)

US30212P3038 - Common Stock - After market: 119.9 -0.3 (-0.25%)


Fundamental Rating

4

Taking everything into account, EXPE scores 4 out of 10 in our fundamental rating. EXPE was compared to 143 industry peers in the Hotels, Restaurants & Leisure industry. EXPE has a medium profitability rating, but doesn't score so well on its financial health evaluation. EXPE is not priced too expensively while it is growing strongly. Keep and eye on this one!




Profitability

Profitability Rating

4

The Piotroski-F score of EXPE is 8.00. This is a very strong score and indicates great health and profitability for EXPE.
EXPE has a Return On Assets of 2.06%. This is below the industry average of 6.32%. 92% of the industry peers outperform EXPE.

EXPE has a Return On Equity of 19.89%. This is below the industry average of 26.90%.
EXPE's Profit Margin of 3.98% is worse than the rest of the industry. The industry average Profit Margin is 10.02%. 84% of the industry peers have a better Profit Margin.
VS Industry

ROA (2.06%) VS Industry: 8% outperformed.

0.25
59.88

ROE (19.89%) VS Industry: 40% outperformed.

0.53
809.18

Profit Margin (3.98%) VS Industry: 16% outperformed.

0.39
31,293.41

Valuation

Valuation Rating

5

The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
Compared to an average industry Enterprise Value to EBITDA ratio of 13.72, EXPE is valued rather cheaply
With a Price/Earnings Ratio of 18.21, EXPE is valued on the expensive side.
Compared to an average industry Price/Earning Ratio of 21.53, EXPE is valued in line with its industry peers.

The Forward Price/Earnings Ratio of 12.54 indicates a correct valuation of EXPE.
With a price book ratio of 8.27, EXPE is valued correctly.
Compared to an average industry price book ratio of 3.53, EXPE is valued more expensive than its industry peers.
VS Industry

Price/Earnings (18.21) VS Industry: 60% outperformed.

277.57
1.71

Price/Book (8.27) VS Industry: 23% outperformed.

207.12
0.17

Enterprise Value/ EBITDA (9.89) VS Industry: 67% outperformed.

205.30
3.68

Growth

Growth Rating

7

EXPE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 392.04%, which is quite impressive.
EXPE is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 59.96% yearly.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
EXPE shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.49%.

The Revenue is expected to grow by 12.83% on average over the next 5 years. This is quite good.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
Measured over the past 5 years, EXPE shows a decrease in Revenue. The Revenue has been decreasing by -0.40% on average per year.
The earnings per share for EXPE have been decreasing by -20.38% on average. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-20.38% -37.19% 392.04% 408.06% 158.05% 100.05% 59.96%
Revenue-0.4% -8.5% 56.49% 36.03% 21.91% 17.43% 12.83%

Health

Health Rating

2

The Piotroski-F score of EXPE is 8.00. This is a very strong score and indicates great health and profitability for EXPE.
EXPE has a Current Ratio of 0.83. This is a bad value and indicates that EXPE is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Current Ratio of 1.12, EXPE is worse placed to pay its short term obligations than its industry peers.
A Quick Ratio of 0.83 indicates that EXPE may have some problems paying its short term obligations.

When comparing the Quick Ratio of EXPE to the average industry Current Ratio of 1.01, EXPE is less able to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.98, EXPE is more dependent on financing than its industry peers.
EXPE has an Altman-Z score of 1.07. This is a bad value and indicates that EXPE is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of EXPE to the average industry Altman-Z score of 1.38, EXPE is less financially healthy than its industry peers.
VS Industry

Debt/Equity (2.75) VS Industry: 26% outperformed.

88.03
0.00

Quick Ratio (0.83) VS Industry: 40% outperformed.

0.00
17.41

Current Ratio (0.83) VS Industry: 35% outperformed.

0.00
17.41

Altman-Z (1.07) VS Industry: 39% outperformed.

-74,230.45
53.98

Dividend

Dividend Rating

0

No dividends for EXPE!.

EXPEDIA GROUP INC120.2

NASDAQ:EXPE (2/7/2023, 7:00:03 PM)+1.13 (+0.95%)

After market: 119.9 -0.3 (-0.25%)

Chartmill FA Rating
GICS Sector Consumer Discretionary
GICS IndustryGroup Consumer Services
GICS Industry Hotels, Restaurants & Leisure
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-08 2023-02-08/amc
Inst Owners 90.91% Inst Owner Change -1.04%
Ins Owners 0.37% Ins Owner Change 2.75%
Market Cap 18.76B Analysts 73.16
Price Target 127.95 (6.45%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP 3.77%
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 9.61%
Min EPS beat(2) -3.65% Max EPS beat(2) 22.88%
EPS beat(4) 3 Avg EPS beat(4) 24.21%
Min EPS beat(4) -3.65% Max EPS beat(4) 51.5%
Revenue beat(2) 1 Avg Revenue beat(2) 1.48%
Min Revenue beat(2) -1.44% Max Revenue beat(2) 4.4%
Revenue beat(4) 1 Avg Revenue beat(4) -0.26%
Min Revenue beat(4) -2.98% Max Revenue beat(4) 4.4%
PT rev (1m) -1.28% PT rev (3m) -11.54%
EPS NQ rev (1m) -0.63% EPS NQ rev (3m) -0.91%
EPS NY rev (1m) 0% EPS NY rev (3m) 2.61%
Revenue NQ rev (1m) -0.25% Revenue NQ rev (3m) -1.07%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -0.02%

Valuation
Industry RankSector Rank
PE 18.21
Fwd PE 12.54
P/S 1.66
P/FCF 5.72
P/OCF 4.8
P/B 8.27
P/tB N/A
EV/EBITDA 9.89
EPS(TTM) 6.6 EY 5.49%
EPS(NY) 9.59 Fwd EY 7.98%
FCF(TTM) 21.01 FCFY 17.48%
OCF(TTM) 25.03 OCFY 20.82%
SpS 72.57 BVpS 14.53
TBVpS -38.85 PEG (NY) 0.04
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA 2.06%
ROE 19.89%
ROIC 9.14%
ROICexc 16.06%
ROICexgc N/A
OM 10.99%
PM 3.98%
GM 85.52%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y -31.43% ROICexc growth 5Y -14.26%
OM growth 3Y -24.13% OM growth 5Y -13.9%
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -0.08% GM growth 5Y 0.12%
F-Score 8 Asset Turnover 0.52

Health
Industry RankSector Rank
Debt/Equity 2.75
Debt/FCF 1.9
Debt/EBITDA 3.06
Cap/Depr 79.29%
Profit Quality 727.05%
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z 1.07
F-Score 8 WACC 10.6%
ROIC/WACC N/A Cap/Depr(3y) 94.93%
Cap/Depr(5y) 90.47% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 392.04% EPS 3Y -37.19%
EPS 5Y -20.38% EPS growth Q2Q 14.73%
EPS Next Y 408.06% EPS Next 2Y 158.05%
EPS Next 3Y 100.05% EPS Next 5Y 59.96%
Revenue growth 1Y 56.49% Revenue growth 3Y -8.5%
Revenue growth 5Y -0.4% Revenue growth Q2Q 22.18%
Revenue Next Year 36.03% Revenue Next 2Y 21.91%
Revenue Next 3Y 17.43% Revenue Next 5Y 12.83%
EBIT growth 1Y 446.8% EBIT growth 3Y -30.58%
EBIT growth 5Y -14.25% EBIT Next Year 318.02%
EBIT Next 3Y 75.56% EBIT Next 5Y 44.57%
FCF growth 1Y 180.51% FCF growth 3Y 41%
FCF growth 5Y 30.42% OCF growth 1Y 225.71%
OCF growth 3Y 23.81% OCF growth 5Y 19.1%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA